The Experts below are selected from a list of 64368 Experts worldwide ranked by ideXlab platform

Mariana Castells - One of the best experts on this subject based on the ideXlab platform.

Pascal Demoly - One of the best experts on this subject based on the ideXlab platform.

  • Important questions in drug allergy and hypersensitivity: consensus papers from the 2018 AAAAI/WAO international drug allergy symposium
    World Allergy Organization Journal, 2018
    Co-Authors: Pascal Demoly, Mariana Castells
    Abstract:

    This article is one of a series of international consensus documents developed from the International Drug Allergy Symposium held at the Joint Congress of the American Academy of Allergy, Asthma & Immunology/World Allergy Organization on March 1, 2018, in Orlando, Florida, USA. The symposium was sponsored by The Journal of Allergy and Clinical Immunology, The Journal of Allergy and Clinical Immunology: In Practice, and The World Allergy Organization Journal and chaired by Mariana Castells, MD, PhD, and Pascal Demoly, MD, PhD.

  • important questions in drug allergy and hypersensitivity consensus papers from the 2018 aaaai wao international drug allergy symposium
    World Allergy Organization Journal, 2018
    Co-Authors: Pascal Demoly, Mariana Castells
    Abstract:

    This article is one of a series of international consensus documents developed from the International Drug Allergy Symposium held at the Joint Congress of the American Academy of Allergy, Asthma & Immunology/World Allergy Organization on March 1, 2018, in Orlando, Florida, USA. The symposium was sponsored by The Journal of Allergy and Clinical Immunology, The Journal of Allergy and Clinical Immunology: In Practice, and The World Allergy Organization Journal and chaired by Mariana Castells, MD, PhD, and Pascal Demoly, MD, PhD.

  • mise a jour sur l immunotherapie allergenique rapport de consensus practall de l aaaai american academy of allergy asthma and Immunology et de l eaaci european academy of allergy and Clinical Immunology
    Revue Francaise D Allergologie, 2014
    Co-Authors: A W Burks, Pascal Demoly, Moises A Calderon, Thomas B Casale, Marek Jutel, L Cox, Harald Nelson, Cezmi A Akdis
    Abstract:

    Resume L’immunotherapie allergenique (ITA) est une methode efficace dans le traitement de l’asthme et de la rhinite allergiques ainsi que de l’anaphylaxie induite par le venin d’hymenopteres. Outre la reduction des symptomes de la maladie, l’ITA peut modifier l’evolution de la maladie allergique et avoir une efficacite a long terme, en induisant une tolerance specifique de l’allergene. En pratique clinique courante, l’immunotherapie est administree par voie sous-cutanee (ITSC) ou par voie sublinguale (ITSL) ; certains allergenes, comme le pollen de graminees, peuvent etre administres par l’une ou l’autre de ces voies alors que d’autres allergenes, comme le venin d’insecte, ne sont administres que par voie sous-cutanee. La duree de l’efficacite de l’ITSC ou de l’ITSL semble etre de 12 ans ; ces deux traitements peuvent prevenir le developpement de l’asthme et l’apparition d’une sensibilisation a de nouveaux allergenes. Malgre les progres accomplis en ITA, des strategies plus sures et plus efficaces s’averent necessaires, en particulier pour les patients souffrant d’asthme, de dermatite atopique ou d’allergie alimentaire. Les nouvelles approches d’amelioration de l’ITA font appel a l’utilisation d’adjuvants ou d’allergenes recombinants et de nouvelles voies d’administration. Dans le cadre des initiatives PRACTALL, l’EAACI (European Academy of Allergy and Clinical Immunology) et l’AAAAI (American Academy of Allergy, Asthma and Immunology) ont nomme un groupe d’experts dont la mission est d’etablir un rapport exhaustif de consensus sur les mecanismes de l’ITA et sur son utilisation en pratique clinique ainsi que sur les besoins non satisfaits et les developpements en cours en ITA. Ce rapport a recu l’aval des deux academies.

  • update on allergy immunotherapy american academy of allergy asthma Immunology european academy of allergy and Clinical Immunology practall consensus report
    The Journal of Allergy and Clinical Immunology, 2013
    Co-Authors: A W Burks, Pascal Demoly, Moises A Calderon, Thomas B Casale, Marek Jutel, Harold S Nelson, Cezmi A Akdis
    Abstract:

    Allergy immunotherapy (AIT) is an effective treatment for allergic asthma and rhinitis, as well as venom-induced anaphylaxis. In addition to reducing symptoms, AIT can change the course of allergic disease and induce allergen-specific immune tolerance. In current Clinical practice immunotherapy is delivered either subcutaneously or sublingually; some allergens, such as grass pollen, can be delivered through either route, whereas others, such as venoms, are only delivered subcutaneously. Both subcutaneous and sublingual immunotherapy appear to have a duration of efficacy of up to 12 years, and both can prevent the development of asthma and new allergen sensitivities. In spite of the advances with AIT, safer and more effective AIT strategies are needed, especially for patients with asthma, atopic dermatitis, or food allergy. Novel approaches to improve AIT include use of adjuvants or recombinant allergens and alternate routes of administration. As part of the PRACTALL initiatives, the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology nominated an expert team to develop a comprehensive consensus report on the mechanisms of AIT and its use in Clinical practice, as well as unmet needs and ongoing developments in AIT. This resulting report is endorsed by both academies.

Antonella Muraro - One of the best experts on this subject based on the ideXlab platform.

  • precision medicine in allergic disease food allergy drug allergy and anaphylaxis practall document of the european academy of allergy and Clinical Immunology and the american academy of allergy asthma and Immunology
    Allergy, 2017
    Co-Authors: Antonella Muraro, Wesley Burks, Robert F. Lemanske, Hansuwe Simon, Carsten Bindslevjensen, David A. Khan, Lars K. Poulsen, Maria J Torres, Mariana Castells, Hugh A. Sampson
    Abstract:

    This consensus document summarizes the current knowledge on the potential for precision medicine in food allergy, drug allergy, and anaphylaxis under the auspices of the PRACTALL collaboration platform. PRACTALL is a joint effort of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology, which aims to synchronize the European and American approaches to allergy care. Precision medicine is an emerging approach for disease treatment based on disease endotypes, which are phenotypic subclasses associated with specific mechanisms underlying the disease. Although significant progress has been made in defining endotypes for asthma, definitions of endotypes for food and drug allergy or for anaphylaxis lag behind. Progress has been made in discovery of biomarkers to guide a precision medicine approach to treatment of food and drug allergy, but further validation and quantification of these biomarkers are needed to allow their translation into practice in the Clinical management of allergic disease.

  • the microbiome in allergic disease current understanding and future opportunities 2017 practall document of the american academy of allergy asthma Immunology and the european academy of allergy and Clinical Immunology
    The Journal of Allergy and Clinical Immunology, 2017
    Co-Authors: Yvonne J Huang, Antonella Muraro, Donald Y M Leung, Benjamin J Marsland, Supinda Bunyavanich, Liam Omahony, Thomas A Fleisher
    Abstract:

    PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and Immunology. PRACTALL 2017 is focused on what has been established regarding the role of the microbiome in patients with asthma, atopic dermatitis, and food allergy. This is complemented by outlining important knowledge gaps regarding its role in allergic disease and delineating strategies necessary to fill these gaps. In addition, a review of progress in approaches used to manipulate the microbiome will be addressed, identifying what has and has not worked to serve as a baseline for future directions to intervene in allergic disease development, progression, or both.

  • precision medicine in patients with allergic diseases airway diseases and atopic dermatitis practall document of the european academy of allergy and Clinical Immunology and the american academy of allergy asthma Immunology
    The Journal of Allergy and Clinical Immunology, 2016
    Co-Authors: Antonella Muraro, Robert F. Lemanske, Lars K. Poulsen, Cezmi A Akdis, T Bieber, Thomas B Casale, Marek Jutel, Peter Hellings, Peck Y Ong, Peter Schmidgrendelmeier
    Abstract:

    In this consensus document we summarize the current knowledge on major asthma, rhinitis, and atopic dermatitis endotypes under the auspices of the PRACTALL collaboration platform. PRACTALL is an initiative of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology aiming to harmonize the European and American approaches to best allergy practice and science. Precision medicine is of broad relevance for the management of asthma, rhinitis, and atopic dermatitis in the context of a better selection of treatment responders, risk prediction, and design of disease-modifying strategies. Progress has been made in profiling the type 2 immune response-driven asthma. The endotype driven approach for non-type 2 immune response asthma, rhinitis, and atopic dermatitis is lagging behind. Validation and qualification of biomarkers are needed to facilitate their translation into pathway-specific diagnostic tests. Wide consensus between academia, governmental regulators, and industry for further development and application of precision medicine in management of allergic diseases is of utmost importance. Improved knowledge of disease pathogenesis together with defining validated and qualified biomarkers are key approaches to precision medicine.

  • consensus communication on early peanut introduction and the prevention of peanut allergy in high risk infants
    World Allergy Organization Journal, 2015
    Co-Authors: David Fleischer, Antonella Muraro, Dianne E Campbell, Susanne Halken, Scott Sicherer, Matthew Greenhawt, Edmond Chan, Yitzhak Katz, Motohiro Ebisawa, Lawrence F Eichenfield
    Abstract:

    The purpose of this brief communication is to highlight emerging evidence to existing guidelines regarding potential benefits of supporting early, rather than delayed, peanut introduction during the period of complementary food introduction in infants. This document should be considered as interim guidance based on consensus among the following organizations: American Academy of Allergy, Asthma & Immunology, American Academy of Pediatrics, American College of Allergy, Asthma & Immunology, Australasian Society of Clinical Immunology and Allergy, Canadian Society of Allergy and Clinical Immunology, European Academy of Allergy and Clinical Immunology, Israel Association of Allergy and Clinical Immunology, Japanese Society for Allergology, Society for Pediatric Dermatology, and World Allergy Organization. More formal guidelines regarding early-life, complementary feeding practices and the risk of allergy development will follow in the next year from the National Institute of Allergy and Infectious Diseases-sponsored Working Group and the European Academy of Allergy and Clinical Immunology.

  • anaphylaxis guidelines from the european academy of allergy and Clinical Immunology
    Allergy, 2014
    Co-Authors: Antonella Muraro, Alexandra F Santos, Graham Roberts, Margitta Worm, M B Bilo, Knut Brockow, Fernandez M Rivas
    Abstract:

    Anaphylaxis is a Clinical emergency, and all healthcare professionals should be familiar with its recognition and acute and ongoing management. These guidelines have been prepared by the European Academy of Allergy and Clinical Immunology (EAACI) Taskforce on Anaphylaxis. They aim to provide evidence-based recommendations for the recognition, risk factor assessment, and the management of patients who are at risk of, are experiencing, or have experienced anaphylaxis. While the primary audience is allergists, these guidelines are also relevant to all other healthcare professionals. The development of these guidelines has been underpinned by two systematic reviews of the literature, both on the epidemiology and on Clinical management of anaphylaxis. Anaphylaxis is a potentially life-threatening condition whose Clinical diagnosis is based on recognition of a constellation of presenting features. First-line treatment for anaphylaxis is intramuscular adrenaline. Useful second-line interventions may include removing the trigger where possible, calling for help, correct positioning of the patient, high-flow oxygen, intravenous fluids, inhaled short-acting bronchodilators, and nebulized adrenaline. Discharge arrangements should involve an assessment of the risk of further reactions, a management plan with an anaphylaxis emergency action plan, and, where appropriate, prescribing an adrenaline auto-injector. If an adrenaline auto-injector is prescribed, education on when and how to use the device should be provided. Specialist follow-up is essential to investigate possible triggers, to perform a comprehensive risk assessment, and to prevent future episodes by developing personalized risk reduction strategies including, where possible, commencing allergen immunotherapy. Training for the patient and all caregivers is essential. There are still many gaps in the evidence base for anaphylaxis.

Mamidipudi Thirumala Krishna - One of the best experts on this subject based on the ideXlab platform.

  • a uk national survey of investigations for beta lactam hypersensitivity heterogeneity in practice and a need for national guidelines on behalf of british society for allergy and Clinical Immunology bsaci
    Clinical & Experimental Allergy, 2013
    Co-Authors: Alex Richter, Shuaib Nasser, Mamidipudi Thirumala Krishna
    Abstract:

    Background Beta lactams (BL) are the most widely prescribed antibiotics in the UK and the commonest cause of hypersensitivity reactions. There are no UK guidelines for BL testing and the most relevant guidelines were devised by the European Network for Drug Allergy (ENDA) on behalf of the European Academy of Allergy and Clinical Immunology. Objective Delivery of allergy services differs across Europe, so this survey was designed to investigate how closely UK practice adhered to these guidelines. Methods An online survey, using surveymonkey.com software, was sent to all consultants offering an allergy service in the UK and who were members of either BSACI or 'Travellers' (Immunology consultant group). Results The response rate was 48% (n=81/165) and BL allergy testing was undertaken by 78% of respondents. All responders requested SsIgE, although four responders stated they rarely requested. Skin testing was undertaken by 87% of respondents who perform beta lactam testing with 17% undertaking skin prick testing (SPT) only, 77% SPT followed by intra-dermal testing (IDT) if the former were negative or indeterminate and 6% SPT and IDT in all cases. The drugs, doses and protocols for skin testing varied considerably. Drug provocation testing was undertaken by 87% of respondents who undertake beta lactam testing with significant heterogeneity in protocols. Respondents that investigated ≤ 20 patients per year demonstrated lower adherence to ENDA recommendations compared to those who saw > 20. Following positive testing, 79% advised avoidance of all penicillins only and the remainder advised additional drug avoidance. Conclusion and Clinical relevance This survey revealed variation in the investigation and management of BL hypersensitivity in the UK with some centres reporting procedures that could potentially put patients at risk of anaphylaxis if allergy was falsely excluded. This survey highlights an urgent need for evidence based national guidelines and standardisation of practice.

  • diagnosis and management of hymenoptera venom allergy british society for allergy and Clinical Immunology bsaci guidelines
    Clinical & Experimental Allergy, 2011
    Co-Authors: Mamidipudi Thirumala Krishna, Susan Leech, Pamela W. Ewan, Lavanya Diwakar, Stephen R Durham, Anthony J Frew, Shuaib Nasser
    Abstract:

    This guidance for the management of patients with hymenoptera venom allergy has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well as on expert opinion and is for use by both adult physicians and pediatricians practising allergy. During the development of these guidelines, all BSACI members were included in the consultation process using a web-based system. Their comments and suggestions were carefully considered by the SOCC. Where evidence was lacking, consensus was reached by the experts on the committee. Included in this guideline are epidemiology, risk factors, Clinical features, diagnostic tests, natural history of hymenoptera venom allergy and guidance on undertaking venom immunotherapy (VIT). There are also separate sections on children, elevated baseline tryptase and mastocytosis and mechanisms underlying VIT. Finally, we have made recommendations for potential areas of future research.

  • Clinical Immunology review series an approach to desensitization
    Clinical and Experimental Immunology, 2011
    Co-Authors: Mamidipudi Thirumala Krishna, Aarnoud P Huissoon
    Abstract:

    Allergen immunotherapy describes the treatment of allergic disease through administration of gradually increasing doses of allergen. This form of immune tolerance induction is now safer, more reliably efficacious and better understood than when it was first formally described in 1911. In this paper the authors aim to summarize the current state of the art in immunotherapy in the treatment of inhalant, venom and drug allergies, with specific reference to its practice in the United Kingdom. A practical approach has been taken, with reference to current evidence and guidelines, including illustrative protocols and vaccine schedules. A number of novel approaches and techniques are likely to change considerably the way in which we select and treat allergy patients in the coming decade, and these advances are previewed.

Shuaib Nasser - One of the best experts on this subject based on the ideXlab platform.

  • a uk national survey of investigations for beta lactam hypersensitivity heterogeneity in practice and a need for national guidelines on behalf of british society for allergy and Clinical Immunology bsaci
    Clinical & Experimental Allergy, 2013
    Co-Authors: Alex Richter, Shuaib Nasser, Mamidipudi Thirumala Krishna
    Abstract:

    Background Beta lactams (BL) are the most widely prescribed antibiotics in the UK and the commonest cause of hypersensitivity reactions. There are no UK guidelines for BL testing and the most relevant guidelines were devised by the European Network for Drug Allergy (ENDA) on behalf of the European Academy of Allergy and Clinical Immunology. Objective Delivery of allergy services differs across Europe, so this survey was designed to investigate how closely UK practice adhered to these guidelines. Methods An online survey, using surveymonkey.com software, was sent to all consultants offering an allergy service in the UK and who were members of either BSACI or 'Travellers' (Immunology consultant group). Results The response rate was 48% (n=81/165) and BL allergy testing was undertaken by 78% of respondents. All responders requested SsIgE, although four responders stated they rarely requested. Skin testing was undertaken by 87% of respondents who perform beta lactam testing with 17% undertaking skin prick testing (SPT) only, 77% SPT followed by intra-dermal testing (IDT) if the former were negative or indeterminate and 6% SPT and IDT in all cases. The drugs, doses and protocols for skin testing varied considerably. Drug provocation testing was undertaken by 87% of respondents who undertake beta lactam testing with significant heterogeneity in protocols. Respondents that investigated ≤ 20 patients per year demonstrated lower adherence to ENDA recommendations compared to those who saw > 20. Following positive testing, 79% advised avoidance of all penicillins only and the remainder advised additional drug avoidance. Conclusion and Clinical relevance This survey revealed variation in the investigation and management of BL hypersensitivity in the UK with some centres reporting procedures that could potentially put patients at risk of anaphylaxis if allergy was falsely excluded. This survey highlights an urgent need for evidence based national guidelines and standardisation of practice.

  • diagnosis and management of hymenoptera venom allergy british society for allergy and Clinical Immunology bsaci guidelines
    Clinical & Experimental Allergy, 2011
    Co-Authors: Mamidipudi Thirumala Krishna, Susan Leech, Pamela W. Ewan, Lavanya Diwakar, Stephen R Durham, Anthony J Frew, Shuaib Nasser
    Abstract:

    This guidance for the management of patients with hymenoptera venom allergy has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well as on expert opinion and is for use by both adult physicians and pediatricians practising allergy. During the development of these guidelines, all BSACI members were included in the consultation process using a web-based system. Their comments and suggestions were carefully considered by the SOCC. Where evidence was lacking, consensus was reached by the experts on the committee. Included in this guideline are epidemiology, risk factors, Clinical features, diagnostic tests, natural history of hymenoptera venom allergy and guidance on undertaking venom immunotherapy (VIT). There are also separate sections on children, elevated baseline tryptase and mastocytosis and mechanisms underlying VIT. Finally, we have made recommendations for potential areas of future research.

  • British Society for Allergy and Clinical Immunology guidelines for the management of egg allergy
    Clinical & Experimental Allergy, 2010
    Co-Authors: Andrew Clark, Isabel Skypala, Susan Leech, Pamela W. Ewan, P. Dugué, N. Brathwaite, Pia A. J. Huber, Shuaib Nasser
    Abstract:

    This guideline advises on the management of patients with egg allergy. Most commonly, egg allergy presents in infancy, with a prevalence of approximately 2% in children and 0.1% in adults. A clear Clinical history and the detection of egg white-specific IgE (by skin prick test or serum assay) will confirm the diagnosis in most cases. Egg avoidance advice is the cornerstone of management. Egg allergy often resolves and re-introduction can be achieved at home if reactions have been mild and there is no asthma. Patients with a history of severe reactions or asthma should have reintroduction guided by a specialist. All children with egg allergy should receive measles, mumps and rubella (MMR) vaccination. Influenza and yellow fever vaccines should only be considered in egg-allergic patients under the guidance of an allergy specialist. This guideline was prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI) and is intended for allergists and others with a special interest in allergy. The recommendations are evidence-based but where evidence was lacking consensus was reached by the panel of specialists on the committee. The document encompasses epidemiology, risk factors, diagnosis, treatment, prognosis and co-morbid associations.